MX2019008438A - Estrogen receptor modulators. - Google Patents

Estrogen receptor modulators.

Info

Publication number
MX2019008438A
MX2019008438A MX2019008438A MX2019008438A MX2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
receptor modulators
5and
compounds
processes
Prior art date
Application number
MX2019008438A
Other languages
Spanish (es)
Inventor
Yang Bin
Christophe Barlaam Bernard
Wilhelmus Maria Nissink Johannes
Andrew Moss Thomas
Jayne Hughes Samantha
Stewart Scott James
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2019008438A publication Critical patent/MX2019008438A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The specification relates to compounds of Formula (I): (I) 5and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
MX2019008438A 2017-01-30 2018-01-29 Estrogen receptor modulators. MX2019008438A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
MX2019008438A true MX2019008438A (en) 2019-10-30

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008438A MX2019008438A (en) 2017-01-30 2018-01-29 Estrogen receptor modulators.

Country Status (36)

Country Link
US (3) US10221173B2 (en)
EP (2) EP3494116B1 (en)
JP (1) JP6951451B2 (en)
KR (1) KR102246668B1 (en)
CN (1) CN110214140B (en)
AU (1) AU2018211495B2 (en)
BR (1) BR112019015389A2 (en)
CA (1) CA3050337A1 (en)
CL (1) CL2019001991A1 (en)
CO (1) CO2019008941A2 (en)
CR (1) CR20190379A (en)
CY (1) CY1122731T1 (en)
DK (1) DK3494116T3 (en)
DO (1) DOP2019000183A (en)
EC (1) ECSP19062381A (en)
ES (2) ES2766249T3 (en)
HU (1) HUE047761T2 (en)
IL (1) IL268263B (en)
JO (1) JOP20190183B1 (en)
LT (1) LT3494116T (en)
MA (1) MA52555A (en)
MX (1) MX2019008438A (en)
MY (1) MY196317A (en)
NI (1) NI201900080A (en)
PE (1) PE20191500A1 (en)
PH (1) PH12019501724A1 (en)
PL (1) PL3494116T3 (en)
PT (1) PT3494116T (en)
RS (1) RS59770B1 (en)
SG (1) SG11201906767XA (en)
SI (1) SI3494116T1 (en)
TN (1) TN2020000009A1 (en)
TW (1) TWI794205B (en)
UA (1) UA125043C2 (en)
WO (1) WO2018138303A1 (en)
ZA (1) ZA201904696B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015419B1 (en) 2016-02-05 2024-01-30 Inventisbio Llc SELECTIVE ESTROGEN RECEPTOR DEGRADANTS, THEIR USES, AND PHARMACEUTICAL COMPOSITION
JOP20190144A1 (en) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the jak family of kinases
RS63500B1 (en) 2016-12-16 2022-09-30 Janssen Pharmaceutica Nv Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
TW202016110A (en) 2018-06-15 2020-05-01 比利時商健生藥品公司 Small molecule inhibitors of the jak family of kinases
WO2021055749A1 (en) * 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
CN115557920B (en) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 Light-emitting auxiliary material, preparation method thereof and organic electroluminescent device

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
BR0113176A (en) 2000-08-10 2003-06-17 Pharmacia Italia Spa Bicyclo-pyrazole compounds, pharmaceutical compositions comprising the compounds, use of the compounds in the manufacture of medicaments, processes for the preparation of the compounds, combinatorial chemical collection and methods for the treatment of mammals including humans using the compounds.
US8008076B2 (en) * 2004-04-27 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Method of producing a nucleic acid encoding an antibody
JP2008534496A (en) 2005-03-22 2008-08-28 アストラゼネカ・アクチエボラーグ Novel tetrahydro-1H-pyrido [4,3-b] indole derivatives as CB1 'receptor ligands
FR2884252B1 (en) 2005-04-08 2007-05-18 Aventis Pharma Sa NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY
AR058223A1 (en) 2005-11-25 2008-01-23 Palau Pharma Sa A COMMITTEE OF PIRAZOLOISOQUINOLINE DERIVATIVES, A PROCEDURE FOR THE PREPARATION OF SUCH COMPOUND AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20120157402A1 (en) * 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
US20120157401A1 (en) * 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
MX348817B (en) 2009-05-27 2017-06-30 Ptc Therapeutics Inc Methods for treating cancer and non-neoplastic conditions.
ES2627692T3 (en) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
EP3004090B1 (en) 2013-05-28 2017-10-25 Astrazeneca AB Chemical compounds
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
MX2015017655A (en) 2013-06-19 2016-04-15 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof.
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
US9980947B2 (en) 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
JP2017538727A (en) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
JP6807841B2 (en) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Estrogen receptor modulator and its use
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
WO2016202161A1 (en) 2015-06-16 2016-12-22 江苏恒瑞医药股份有限公司 Piperidine derivative and preparation method and pharmaceutical use thereof
CN106518768B (en) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 Acrylic acid derivative, preparation method and medical application thereof
EP3912680A1 (en) 2015-10-01 2021-11-24 Olema Pharmaceuticals, Inc. Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
US10399939B2 (en) 2015-11-09 2019-09-03 Genentech, Inc. Tetrahydronaphthalene estrogen receptor modulators and uses thereof
CN107428758B (en) 2015-11-12 2020-08-04 浙江海正药业股份有限公司 Acrylic acid derivative, preparation method and medical application thereof
US10398689B2 (en) 2015-12-22 2019-09-03 Jiangsu Hengrui Medicine Co., Ltd. Benzopiperidine derivative, preparation method thereof and medical use thereof
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (en) 2016-04-20 2018-02-01 阿斯特捷利康公司 Chemical compounds
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
CN109415361B (en) 2016-06-29 2022-03-08 浙江海正药业股份有限公司 Acrylic acid derivative, preparation method thereof and application thereof in medicine
WO2018019793A1 (en) * 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN107814798B (en) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-substituted acrylic acid compound and preparation method and application thereof
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
MX2019004685A (en) 2016-10-24 2019-08-21 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer.
BR102016024814A2 (en) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. Compound, Compounding Process, Pharmaceutical Composition, Compound Use, and Method of Treatment of Psychiatric Disorders and / or Sleep Disorders
PE20190977A1 (en) 2016-12-16 2019-07-09 Lilly Co Eli 7-PHENYLETHYLAMINE-4H-PYRIMID COMPOUNDS [4,5-D] [1,3] -OXAZIN-2-ONA AS INHIBITORS OF IDH1 AND IHD2 MUTANTS
ES2934789T3 (en) 2016-12-16 2023-02-27 Pfizer glp-1 receptor agonists and uses thereof
JOP20190144A1 (en) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the jak family of kinases
TWI831738B (en) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
RS63500B1 (en) 2016-12-16 2022-09-30 Janssen Pharmaceutica Nv Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
RU2019121534A (en) 2016-12-16 2021-01-18 Басф Се PESTICIDAL COMPOUNDS
WO2018138293A1 (en) 2017-01-30 2018-08-02 Chiesi Farmaceutici S.P.A. Tyrosine amide derivatives as rho- kinase inhibitors

Also Published As

Publication number Publication date
KR102246668B1 (en) 2021-04-29
ZA201904696B (en) 2020-05-27
CN110214140A (en) 2019-09-06
RS59770B1 (en) 2020-02-28
MY196317A (en) 2023-03-24
CL2019001991A1 (en) 2019-10-11
KR20190112767A (en) 2019-10-07
WO2018138303A1 (en) 2018-08-02
CY1122731T1 (en) 2021-05-05
US11046689B2 (en) 2021-06-29
IL268263A (en) 2019-09-26
US20190233413A1 (en) 2019-08-01
JP2020505354A (en) 2020-02-20
TN2020000009A1 (en) 2021-10-04
ES2766249T3 (en) 2020-06-12
LT3494116T (en) 2020-01-10
PE20191500A1 (en) 2019-10-22
IL268263B (en) 2021-10-31
DK3494116T3 (en) 2020-01-27
PH12019501724A1 (en) 2020-06-01
HUE047761T2 (en) 2020-05-28
US20180282325A1 (en) 2018-10-04
TW201840558A (en) 2018-11-16
ES2931320T3 (en) 2022-12-28
CA3050337A1 (en) 2018-08-02
SI3494116T1 (en) 2020-02-28
US20200239468A1 (en) 2020-07-30
NI201900080A (en) 2020-03-18
JP6951451B2 (en) 2021-10-20
EP3689873B1 (en) 2022-09-14
CO2019008941A2 (en) 2019-08-30
UA125043C2 (en) 2021-12-29
EP3494116A1 (en) 2019-06-12
CN110214140B (en) 2022-08-30
DOP2019000183A (en) 2019-07-31
TWI794205B (en) 2023-03-01
MA52555A (en) 2021-03-17
AU2018211495A1 (en) 2019-09-12
EP3689873A1 (en) 2020-08-05
EP3494116B1 (en) 2019-10-23
CR20190379A (en) 2019-10-21
AU2018211495B2 (en) 2020-05-21
US10590132B2 (en) 2020-03-17
JOP20190183B1 (en) 2022-09-15
ECSP19062381A (en) 2019-09-30
JOP20190183A1 (en) 2019-07-28
BR112019015389A2 (en) 2020-03-10
SG11201906767XA (en) 2019-08-27
US10221173B2 (en) 2019-03-05
PT3494116T (en) 2020-01-28
PL3494116T3 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
JOP20210241A1 (en) Fused tricyclic compounds useful as anticancer agents
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
TN2020000009A1 (en) Estrogen receptor modulators
MX2019002180A (en) Muscarinic m1 receptor positive allosteric modulators.
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
PH12021550048A1 (en) Selective estrogen receptor degraders.
TW201613864A (en) Novel compounds
MX2019011265A (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
MX2018009078A (en) Indane derivatives as mglur7 modulators.
TW201613921A (en) Serine derivatives as ghrelin receptor agonists
MX2016011900A (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators.
WO2015138280A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
MX2021004471A (en) Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators.
EA201991734A1 (en) Estrogen Receptor Modulators
EA202092600A1 (en) TETRACYCLIC HETEROARYL COMPOUNDS
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators